




MDH-211 for the Treatment of Intractable Respiratory Disease

MDH-211 (*Proteus mirabilis* EV) is a new class of first-in-class oral therapeutic indicated for intractable respiratory diseases, such as CS-resistant neutrophilic asthma, idiopathic pulmonary fibrosis (IPF), pneumonia, and more

MDH-211

- Naïve (natural) EVs from a single **Proteus** strain



Value Propositions

1. **First-in-class**: a new modality drug with a novel mechanism of action (MoA)
2. **Very safe**: a commensal bacterium *Proteus mirabilis*-derived EVs
3. **Effective**: a disease-modifying therapy against intractable respiratory diseases, including neutrophilic asthma and idiopathic pulmonary fibrosis (IPF)
4. **Convenient administration**: orally-delivered
5. **Affordable**: cost effective production

MDH-211: Key Indications & Development Timeline

Key Indications

- 1) **Idiopathic pulmonary fibrosis (IPF)**
- 2) **Neutrophilic asthma & COPD**
- 3) **Nosocomial pneumonia**
- 4) **Viral pneumonia**
- 5) **Interstitial pneumonitis**

Core patent

- ✓ PCT (KR2018/007144) application date at 25/Jun/2018
- ✓ Registered at KR, US, & JP (as of July 2022)
- ✓ Pending at EU, CN (as of July 2022)

Development Timeline

IND filing ('25)



P1 ('26)



P2 ('28)



Exit